Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients

[1]  Carsten Denkert,et al.  Response-guided neoadjuvant chemotherapy for breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Strobbe,et al.  The Prognostic Value of Lymph Node Ratio in Node-Positive Breast Cancer: A Dutch Nationwide Population-Based Study , 2013, Annals of Surgical Oncology.

[3]  N. Duraker,et al.  Lymph Node Ratio May Be Supplementary to TNM Nodal Classification in Node-positive Breast Carcinoma Based on the Results of 2,151 Patients , 2013, World Journal of Surgery.

[4]  K. Albuquerque,et al.  The Prognostic Value of Lymph Node Cross-Sectional Cancer Area in Node-Positive Breast Cancer: A Comparison with N Stage and Lymph Node Ratio , 2012, Pathology research international.

[5]  H. Verkooijen,et al.  Does the Axillary Lymph Node Ratio Have Any Added Prognostic Value over pN Staging for South East Asian Breast Cancer Patients? , 2012, PloS one.

[6]  A. Giuliano,et al.  Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? , 2012, Clinical & Experimental Metastasis.

[7]  Shuai Li,et al.  Lymph Node Ratio , 2012, International journal of surgical pathology.

[8]  R. Greil,et al.  Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) , 2012, Annals of Surgical Oncology.

[9]  H. Kuerer,et al.  Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy , 2012, Breast Cancer Research.

[10]  Barbara L. Smith,et al.  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Ahn,et al.  Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society , 2011, Breast Cancer Research and Treatment.

[12]  D. Rimm,et al.  Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer , 2011, Annals of surgical oncology.

[13]  K. McMasters,et al.  Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. , 2011, Journal of the American College of Surgeons.

[14]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[16]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[17]  Talia K. Ben-Jacob,et al.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial , 2010, Annals of surgery.

[18]  G. Vlastos,et al.  Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer. , 2010, The oncologist.

[19]  J. Olson,et al.  Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. , 2010, Journal of the American College of Surgeons.

[20]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[22]  W. Woodward,et al.  Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. , 2009, Future oncology.

[23]  S. O'toole,et al.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Hicks,et al.  Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis: Are We Ready? , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[25]  G. Vlastos,et al.  Lymph node ratio as an alternative to pN staging in node-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Woodward,et al.  The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. , 2008, European journal of cancer.

[27]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Woodward,et al.  Prognostic value of nodal ratios in node-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Otter,et al.  The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association? , 2006, Annals of Surgical Oncology.

[30]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[31]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[32]  Daniel Birnbaum,et al.  Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.

[33]  V. Fidler,et al.  Variability in axillary lymph node dissection for breast cancer , 2004, Journal of surgical oncology.

[34]  G. Storme,et al.  The lymph node ratio as prognostic factor in node-positive breast cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[36]  J. Donohue,et al.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. , 2003, Archives of surgery.

[37]  G. Storme,et al.  Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. , 2003, International journal of oncology.

[38]  D. McCready,et al.  Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer , 2003, Journal of surgical oncology.

[39]  M. Boermeester,et al.  Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[40]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  A E Giuliano,et al.  Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S G Hilsenbeck,et al.  Significance of axillary lymph node metastasis in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Kiricuta,et al.  A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma , 1992, Cancer.

[45]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.

[46]  C. Axelsson,et al.  Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). , 1992, European journal of cancer.

[47]  J. Carl,et al.  Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients. , 1990, Acta oncologica.